Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
8 studies found for:    19846889 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting A Multicenter Randomized Open-label Study of Oseltamivir Combined With High-dose Dexamethasone Versus High-dose Dexamethasone in the Management of Immune Thrombocytopenia With High Platelet Desialylation Level
Condition: Thrombocytopenia
Interventions: Drug: Oseltamivir;   Drug: Dexamethasone
2 Completed An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)
Condition: Immune Thrombocytopenia
Intervention: Drug: Dexamethasone
3 Completed rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Interventions: Drug: recombinant human thrombopoietin (rhTPO); dexamethasone;   Drug: Dexamethasone
4 Completed Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Intervention: Drug: rhTPO in combination with Rituximab
5 Completed High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Condition: Purpura, Thrombocytopenic, Idiopathic
Interventions: Drug: Prednisone;   Drug: Dexamethasone
6 Withdrawn Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Interventions: Drug: recombinant human thrombopoietin (rhTPO); rituximab;   Drug: Dexamethasone
7 Recruiting Immune Thrombocytopenia in Pregnancy
Conditions: Immune Thrombocytopenia;   Pregnancy
Intervention: Other: No intervention
8 Completed rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP
Conditions: Purpura;   Idiopathic Thrombocytopenic Purpura
Interventions: Drug: rituximab; recombinant human thrombopoietin (rhTPO);   Drug: Rituximab

Study has passed its completion date and status has not been verified in more than two years.